NewAmsterdam Pharma (NAMS) Equity Ratio (2022 - 2025)
Historic Equity Ratio for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to 0.93.
- NewAmsterdam Pharma's Equity Ratio rose 732.16% to 0.93 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.93, marking a year-over-year increase of 732.16%. This contributed to the annual value of 0.88 for FY2024, which is 544.44% up from last year.
- NewAmsterdam Pharma's Equity Ratio amounted to 0.93 in Q3 2025, which was up 732.16% from 0.96 recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's Equity Ratio ranged from a high of 0.96 in Q2 2025 and a low of 0.73 during Q2 2023
- In the last 4 years, NewAmsterdam Pharma's Equity Ratio had a median value of 0.87 in 2024 and averaged 0.87.
- In the last 5 years, NewAmsterdam Pharma's Equity Ratio crashed by 884.25% in 2023 and then soared by 1917.85% in 2024.
- Quarter analysis of 4 years shows NewAmsterdam Pharma's Equity Ratio stood at 0.91 in 2022, then dropped by 8.84% to 0.83 in 2023, then rose by 5.44% to 0.88 in 2024, then rose by 5.67% to 0.93 in 2025.
- Its Equity Ratio was 0.93 in Q3 2025, compared to 0.96 in Q2 2025 and 0.95 in Q1 2025.